The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

IX.b

Respiratory dyskinesia

Publications

Oyama G, Foote KD, Iyer SS, Zeilman P, Hwynn N, Jacobson CE, Malaty IA, Fernandez HH, Rodriguez RL, Okun MS

Unilateral GPi-DBS as a treatment for levodopa-induced respiratory dyskinesia in Parkinson disease.

The neurologist. 2011;17(5):282-5

Rich MW, Radwany SM

Respiratory dyskinesia. An underrecognized phenomenon.

Chest. 1994;105(6):1826-32

Zupnick HM, Brown LK, Miller A, Moros DA

Respiratory dysfunction due to L-dopa therapy for parkinsonism: diagnosis using serial pulmonary function tests and respiratory inductive plethysmography.

The American journal of medicine. 1990;89(1):109-14